T. Crofts
City Of Hope National Medical Center · 13 works · 1,398 citations · h-index 9
Top works
- Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer
- Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
- Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor
- Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer
- Short Course of Omeprazole
- Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)
- Comparable activity with oral topotecan/cisplatin (TC) and IV etoposide/cisplatin (PE) as treatment for chemotherapy-naïve patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Final results of a randomized phase III trial (389)
- O-157 Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC
- P-569 The relationship between treatment-free interval (TFI) and outcomes to therapy in patients with relapsed Small Cell Lung Cancer (SCLC): A review of 631 patients treated with IV topotecan in 6 studies
- Immediate Reproducibility of Upper Limit of Vulnerability Measurements in Patients Undergoing Transvenous Implantable Cardioverter Defibrillator Implantation
- A randomized phase III trial (389): Oral topotecan/cisplatin (TC) vs IV etoposide/cisplatin (PE) as treatment for chemotherapy-naïve patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Interim tolerability results
- The relationship between tumour response, stabilisation of disease and survival: A meta-analysis of two Phase III studies on topotecan in relapsed ovarian cancer
- The relationship between tumour response, stabilisation of disease and survival: A meta-analysis of two Phase III studies on topotecan in relapsed ovarian cancer